Table 1 Demographic and clinical characteristic of the RA patients
Demographic characteristics of the RA patients | |
Age (years, mean ± SD) | 54 ± 13 |
Sex (female/male) | 4/1 |
Autoantibodies and RA patients with hand RX erosions | |
+RF (n/5 = %) | 3 (60%) |
+ACPA (n/5 = %) | 3 (60%) |
Rx erosions (n/5 = %) | 3 (60%) |
Disease duration (years, mean ± SD) | 6.4 ± 5 |
0–5 years (n/5 = %) | 3 (60%) |
5–10 years (n/5 = %) | 2 (40%) |
> 20 years (n = %) | 0 (0%) |
Comorbidities | |
Hypertension (n/5 = %) | 3 (60%) |
Diabetes (n = %) | 0 (0%) |
Anaemia (n = %) | 0 (0%) |
Sjogren’s syndrome (n = %) | 0 (0%) |
Heart failure (n = %) | 0 (0%) |
Acute cardiac ischemic (ACI) (n = %) | 0 (0%) |
Allergic asthma (n = %) | 0 (0%) |
Dyslipidaemia (n/5 = %) | 1 (20%) |
Neoplasia (n = %) | 0 (0%) |
Osteoporosis (n/5 = %) | 3 (60%) |
Dysthyroid (n/5 = %) | 1 (20%) |
H. pylori (n = %) | 0 (0%) |
HBV (n = %) | 0 (0%) |
NSAID treatment | |
NSAIDs (n/5 = %) | 1(20%) |
Glucocorticoid treatment | |
Prednisone (n/5 = %) | 1 (20%) |
Modified release prednisone (n/5 = %) | 2 (40%) |
csDMARD treatment | |
Methotrexate (n/5 = %) | 3 (60%) |
Leflunomide (20 mg/day) (n/5 = %) | 2 (30%) |
bDMARD treatment | |
TNF inhibitors (n/5 = %) | 1 (20%) |
Abatacept (n = %) | 0 (0%) |
Rituximab (n = %) | 0 (0%) |
Tocilizumab (n = %) | 0 (0%) |
Other treatments | |
Vitamin D (n/5 = %) | 4 (80%) |
Folic acid supplementation (5 mg/week) (n/5 = %) | 3 (60%) |
Clinical score and laboratory findings | |
Tj (mean ± SD) | 5 ± 2.97 |
Sj (mean ± SD) | 1.8 ± 1.47 |
VAS (mean ± SD) | 5.2 ± 2.63 |
CRP (mg/dL, mean ± SD) | 11.36 ± 16.47 |
DAS (CRP) (mean ± SD) | 3.71 ± 0.56 |